1. Composite midazolam and 1′-OH midazolam population pharmacokinetic model for constitutive, inhibited and induced CYP3A activity

   • Sabrina T. Wiebe
   • Andreas D. Meid
   • Gerd Mikus

   Original Paper Open access 08 August 2020 Pages: 527 - 542

   

2. Well-tempered MCMC simulations for population pharmacokinetic models

   • Frederic Y. Bois
   • Nan-Hung Hsieh
   • Brad Reisfeld

   Original paper 31 July 2020 Pages: 543 - 559

   

3. Application of Brunauer–Emmett–Teller (BET) theory and the Guggenheim–Anderson–de Boer (GAB) equation for concentration-dependent, non-saturable cell–cell interaction dose-responses

   • Van Anh Nguyen
   • Murali Ramanathan

   Original Paper 08 August 2020 Pages: 561 - 572

   

4. Bolus pharmacokinetics: moving beyond mass-based dosing to guide drug administration

   • Elie Sarraf

   Original Paper 18 August 2020 Pages: 573 - 581

   

5. The influence of cardiac output on propofol and fentanyl pharmacokinetics and pharmacodynamics in patients undergoing abdominal aortic surgery

   • Agnieszka Bienert
   • Paweł Sobczyński
   • Paweł Wiczling

   Original Paper Open access 25 August 2020 Pages: 583 - 596

   

6. Development of a physiologically-based pharmacokinetic model for ocular disposition of monoclonal antibodies in rabbits

   • David Bussing
   • Dhaval K. Shah

   Original Paper 02 September 2020 Pages: 597 - 612

   

7. Longitudinal analysis of organ-specific tumor lesion sizes in metastatic colorectal cancer patients receiving first line standard chemotherapy in combination with anti-angiogenic treatment

   • Francois Mercier
   • Marion Kerioui
   • Rene Bruno

   Original paper 31 August 2020 Pages: 613 - 625